Androgen Deprivation Therapy for Prostate Cancer and the Risk of Hospitalisation for Community-Acquired Pneumonia

Date of Approval
Application Number
Technical Summary

Androgen deprivation therapy (ADT) is the mainstay treatment in patients with advanced prostate cancer. However, this therapy has been associated with a number of adverse events, including cardiovascular outcomes and fractures. Studies also suggest that ADT may increase the risk of pneumonia, but these have a number of methodological shortcomings. Thus, the objective of this study is to assess whether the use of ADT (including gonadotropin-releasing hormone (GnRH) agonists, oral antiandrogens, and bilateral orchiectomy) is associated with an increased risk of community-acquired pneumonia. This objective will be addressed by assembling a cohort of patients newly-diagnosed with non-metastatic prostate cancer between April 1, 1998 and March 31, 2015. Time-dependent Cox proportional hazard models will be used to estimate adjusted hazard ratios and 95% confidence intervals for a hospitalisation for community-acquired pneumonia (recorded in the Hospital Episode Statistics) associated with current and past use of ADT, compared with no use. Secondary analyses will assess if the risk varies according duration of use, and by specific types of ADT.

Health Outcomes to be Measured

Hospitalisation for community-acquired pneumonia


Samy Suissa - Chief Investigator - McGill University
Blánaid Hicks - Collaborator - Queen's University Belfast
Christina Santella - Collaborator - McGill University
Hui Yin - Collaborator - Sir Mortimer B Davis Jewish General Hospital
Laurent Azoulay - Collaborator - McGill University
Pierre Ernst - Collaborator - McGill University


HES Admitted Patient Care